Clinical difference between cystic fibrosis patients colonized with different bacteria  by Reis, P. et al.
S58 7. Pulmonology
230* Intravenous methylprednisolone pulse therapy vs. oral
prednisone for allergic bronchopulmonary aspergillosis (ABPA)
in CF
M. Cohen-Cymberknoh1, H. Blau2, D. Shoseyov1, O. Efrati3, S. Armoni1,
E. Kerem1. 1CF Center, Hadassah University Hospital, Jerusalem, Israel;
2Schneider Children’s Medical Center, Petah Tikva, Israel; 3Sheba Medical Center,
Tel Hashomer, Israel
The treatment of ABPA consists of prolonged oral corticosteroids and antifungal
therapy which may have severe toxicity. High-dose IV pulse methylprednisolone
therapy (HDIVPMT) is used for autoimmune diseases and was shown to be as
effective as oral prednisone and associated with less side effects.
The purpose of this study was to compare treatment with HDIVPMT to conventional
therapy with oral prednisone in patients with CF suffering from ABPA. Nine patients
(5 females) ages 7−36 years old were treated with HDIVPMT (10mg/kg/d) for 3
days once a month, and 5 patients received oral prednisone (1−2mg/kg/d), until
clinical and laboratory resolution of ABPA signs was noted. All the 14 patients
were also treated with itraconazole.
Results: Both groups showed similar clinical and laboratory improvement (increase
in FEV1, decline in serum IgE levels (total and speciﬁc anti AF), and total
eosinophil counts. The adverse effects in the group that received HDIVPMT were
minor and included ﬂushing, myalgia and restlessness, all of which disappeared
within 3−5 days after the pulse. The duration of therapy was 4−12 pulses. Patients
that received oral prednisone suffered from more serious side effects including
cushingoid facies, hirsutism, severe weight gain, depression, emotional instability
and hypertension, all were reversible only after steroid dose was reduced or stopped.
The duration of oral therapy was much longer and more patients needed repeated
therapies.
In conclusion, pulse methylprednisolone is as effective as oral prednisone with less
serious side effects and therefore is advantageous in the treatment of ABPA in CF.
231 21% prevalence of ABPA in a regional paediatric
Cystic Fibrosis (CF) clinic – how high is too high?
C.A. Byrnes1,2, M. Jaksic1, J.C. Tate1. 1Starship Children’s Hospital, Auckland,
New Zealand; 2University of Auckland, Auckland, New Zealand
Aim: To document the prevalence, severity and response to treatment of ABPA in
children with CF followed up in a single, regional clinic.
Method: Retrospective review of all APBA diagnoses from 2000 to 2007 inclusive
in children 0−15 years of age at the CF Clinic, Starship Children’s Hospital, New
Zealand.
Results: There were 32 episodes of ABPA seen in 16 children (mean age 10 years,
range 4−15 years, 12 males) in the clinic population of 75 giving a prevalence
of 21%. The mean total IgE was 2248 kIU/L (range 174−10,300) and >1000
kIU/L in 23 episodes at time of diagnosis. The eosinophil counts were raised in
9 episodes, all had positive RAST testing and aspergillus precipitans with 15/16
growing aspergillus in sputum. FVC decreased by 22.1% predicted (range 0−65%)
and FEV1 by 23.9% predicted (range 0−70%) during the acute event. There were
no signiﬁcant differences between FVC and FEV1 from last best prior to ABPA
episode and post ABPA treatment. Nine were hospitalised, 2 required intensive care
and 3 needed oxygen. All were treated with oral steroid therapy with mean duration
8.9 months (range 0.5−31 months) and all had oral intraconazole. Novel treatments
were tried because of poor response; 3 children had 4 courses of methylprednisolone
and 3 had nebulised amphotericin. The incidence increased from 3−4 episodes/year
to 8 in 1 year on completion of building works within the hospital.
Discussion: A prevalence of 21% ABPA is higher than previous reports. The disease
described is severe and refractory to treatment. Surprisingly, there was no signiﬁcant
difference in lung function testing before and after the ABPA episodes. Recent
hospital construction and the high background rate of atopy in NZ children may be
factors.
232 Infection with Mycobacterium abscessus deteriorates lung
function dramatically in CF patients
K. Ko¨tz1, M. Gilljam1, A. Lindblad1. 1The West Swedish CF Centre, Queen Silvia
Children’s hospital, Gothenburg, Sweden
Objective: To assess the clinical course in patients with chronic M. abscessus
infection.
Patients: At our centre 5/140 CF patients are chronically infected with M. absces-
sus. All are PI and were between 11 and 25 years old at the time of infection. Two
patients were chronically infected with P. aeruginosa, one with B. cepacia, one with
S. maltophilia and one patient had no other chronic infection. All were treated with
at least three antibiotics and/or IFN-g for 10 till 24 months. Only patient 4 was
BCG-vaccinated as a child.
Results: FEV1 decreased dramatically in 3 patients: 32 and 43% within 7 resp.
41% within 10 years. Two patients developed hearing impairment due to long-term
treatment with amikacin. The fourth patient had an average annual loss of 0.5% in
FEV1%. The ﬁfth patient is infected with M. abscessus since 2
1
2 years. His FEV1
deteriorated severely before detection of M. abscessus but improved after the start
of antibiotic/immunologic treatment.
Conclusions: Three of 5 patients had a long-term decrease of FEV1% despite ag-
gressive therapy causing severe hearing impairment in two patients. A multicenter-
study is warranted to evaluate the most effective treatment.
Patient FEV1%
1 yr before
infection
When
infected
2 yrs after
infection
7 yrs after
infection
10 yrs after
infection
Annual
DFEV1%
& 17 yrs 122 114 113 83 73 −4.1
& 12 12 yrs 114 115 100 83 −4.6
% 11 12 yrs 66 62 51 19 −6.1
% 25 12 yrs 86 81 81 81 76 −0.5
% 11 12 yrs 104 88 97 +4.5
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Introduction: The aim of our study is to analyse the clinical difference between
CF patients (pts) with Staphylococcus aureus (SA), Pseudomonas aeruginosa (PA)
and Burkholderia cepacia (BC) chronic colonization.
Methods: Retrospective review of clinical charts and bacterial isolation of all the
pts followed in 2007. Number of hospitalizations, number of days in hospital and
respiratory function tests (RFT) – FEV1; FEF 25−75 and FVC, were evaluated. Data
were analysed with SPSS 14.0 version, using T-test, two sample, and Man-Whitney
test.
Results: 56 pts were included (55% female; median: 9 years). SA, PA and BC
chronic colonization were found respectively in 41.1% (23/56), 23.2% (13/56) and
4.1% (4/56) of the pts. Pts with no chronic colonization had better results on RFT,
but the difference was not signiﬁcant (p value >5%). Comparing pts with different
bacteria chronic colonization with those who did not have that speciﬁc colonization,
we found that PA and BC colonised pts had worse RFT results. Pts who did not have
PA chronic colonization had better FEV1 (95%CI 3.6−40.1), FEF 25−75 (95%CI
0.5−51.8) and FVC (95%CI 0.3−32.2). Pts with no BC chronic colonization had
higher FEV1 (95%CI 16.5−74.6) and FVC (95%CI (25.9−71.5). There was no
statistical signiﬁcant difference regarding RFT results and SA chronic colonization.
BC colonized pts had higher number of hospitalizations and number of days in
hospital (p: 0.014; p: 0.012). That was not found in the other colonized groups.
Discussion: PTS with PA and BC chronic colonization had worse RFT. This was
not found in SA cases. BC chronic colonization is associated with a higher number
of hospitalizations that last longer.
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